LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Prevencio Presents AI-Driven Platform for Medical Diagnostic Test Development

By LabMedica International staff writers
Posted on 27 Jul 2023
Image: AI-powered blood tests significantly improve diagnoses for heart and blood vessel related complications (Photo courtesy of Prevencio)
Image: AI-powered blood tests significantly improve diagnoses for heart and blood vessel related complications (Photo courtesy of Prevencio)

Prevencio, Inc. (Kirkland, WA, USA) is showcasing its leading-edge, artificial intelligence (AI)-powered HART platform and blood tests at AACC 2023.

Prevencio has announced the culminative presentation of patient data demonstrating that its AI-empowered HART blood tests exhibit high accuracy across a diverse patient demographic, including those affected by diabetes, chronic kidney disease, hypertension, obesity, coronary heart disease, heart failure, chronic total occlusion (CTO) of the heart arteries, and Kawasaki disease. The HART platform is disease agnostic, thereby allowing the development of diagnostics that extend beyond cardiac diseases. Presently, Prevencio's two primary tests, HART CVE and HART CADhs, are accessible to medical professionals for patient use. HART CVE calculates a patient's one-year risk for a heart attack, stroke, or cardiovascular death, whereas HART CADhs evaluates if a patient has a blockage in the heart arteries, indicating an imminent risk of a heart attack. Researchers from Massachusetts General Hospital (MGH, Boston, MA, USA) tested more than 1,250 patients undergoing coronary or peripheral angiography to collaborate in the development and validation of the AI-driven HART platform which has produced seven highly accurate, algorithmic multiple protein blood tests.

“It is impressive the HART tests provide robust accuracy amongst a wide range of patients,” said James L. Januzzi, MD, a practicing cardiologist at MGH, and principal investigator in development, validation, and ongoing testing of six of the seven HART tests. “With the rapid rise in cardiovascular disease, better tools to recognize risk and intervene proactively are needed. Our data suggest that AI-derived, multi-protein, algorithmically scored blood tests may be useful to individualize cardiac risk assessment and foster aggressive primary and secondary cardiovascular prevention. We are especially excited with our most recent data demonstrating the accuracy of HART CVE in assessing risk in patients with total chronic occlusion of the coronary arteries and look forward to using the HART platform to develop additional clinical applications and diagnostic tests.”

Related Links:
Prevencio, Inc.
MGH 

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more